Early cases of SARS-CoV-2 infection in Uganda: epidemiology and lessons learned from risk-based testing approaches - March-April 2020
On March 13, 2020, Uganda instituted COVID-19 symptom screening at its international airport, isolation and SARS-CoV-2 testing for symptomatic persons, and mandatory 14-day quarantine and testing of persons traveling through or from high-risk countries. On March 21, 2020, Uganda reported its first S...
Gespeichert in:
| Veröffentlicht in: | Globalization and health 2020-11, Vol.16 (1), p.114, Article 114 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 114 |
| container_title | Globalization and health |
| container_volume | 16 |
| creator | Migisha, Richard Kwesiga, Benon Mirembe, Bernadette Basuta Amanya, Geofrey Kabwama, Steven N Kadobera, Daniel Bulage, Lilian Nsereko, Godfrey Wadunde, Ignatius Tindyebwa, Tonny Lubwama, Bernard Kagirita, Atek A Kayiwa, John T Lutwama, Julius J Boore, Amy L Harris, Julie R Bosa, Henry Kyobe Ario, Alex Riolexus |
| description | On March 13, 2020, Uganda instituted COVID-19 symptom screening at its international airport, isolation and SARS-CoV-2 testing for symptomatic persons, and mandatory 14-day quarantine and testing of persons traveling through or from high-risk countries. On March 21, 2020, Uganda reported its first SARS-CoV-2 infection in a symptomatic traveler from Dubai. By April 12, 2020, 54 cases and 1257 contacts were identified. We describe the epidemiological, clinical, and transmission characteristics of these cases.
A confirmed case was laboratory-confirmed SARS-CoV-2 infection during March 21-April 12, 2020 in a resident of or traveler to Uganda. We reviewed case-person files and interviewed case-persons at isolation centers. We identified infected contacts from contact tracing records.
Mean case-person age was 35 (±16) years; 34 (63%) were male. Forty-five (83%) had recently traveled internationally ('imported cases'), five (9.3%) were known contacts of travelers, and four (7.4%) were community cases. Of the 45 imported cases, only one (2.2%) was symptomatic at entry. Among all case-persons, 29 (54%) were symptomatic at testing and five (9.3%) were pre-symptomatic. Among the 34 (63%) case-persons who were ever symptomatic, all had mild disease: 16 (47%) had fever, 13 (38%) reported headache, and 10 (29%) reported cough. Fifteen (28%) case-persons had underlying conditions, including three persons with HIV. An average of 31 contacts (range, 4-130) were identified per case-person. Five (10%) case-persons, all symptomatic, infected one contact each.
The first 54 case-persons with SARS-CoV-2 infection in Uganda primarily comprised incoming air travelers with asymptomatic or mild disease. Disease would likely not have been detected in these persons without the targeted testing interventions implemented in Uganda. Transmission was low among symptomatic persons and nonexistent from asymptomatic persons. Routine, systematic screening of travelers and at-risk persons, and thorough contact tracing will be needed for Uganda to maintain epidemic control. |
| doi_str_mv | 10.1186/s12992-020-00643-7 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7686950</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A650661856</galeid><sourcerecordid>A650661856</sourcerecordid><originalsourceid>FETCH-LOGICAL-c531t-b22fdb418681244bc69d04b3d0f4ed4e0efb0e4318c7eaf98283b3af40937d133</originalsourceid><addsrcrecordid>eNptks9uEzEQxlcIREvhBTggS1zg4OJ_8e5yQIqiAhVFIEq5Wl7veOuysYO9QeQBeG8mpJQGIR88sn_z2TPzVdVjzo45b_SLwkXbCsoEo4xpJWl9pzrktVK00UzevRUfVA9KuWJMMSXb-9WBlEK2TPHD6ueJzeOGOFugkOTJ-fzTOV2kL1SQED24KaSIEbkYbOztSwKr0MMypDENG4JHZIRSUiy42xyhJz6nJcmhfKUdavZkgjKFOBC7WuVk3SU-Q8l7m90lna9yGInA_z-s7nk7Fnh0vR9VF69PPi_e0rMPb04X8zPqZpJPtBPC953C2hsulOqcbnumOtkzr6BXwMB3DJTkjavB-rYRjeyk9Yq1su65lEfVq53uat0toXcQp2xHg_9Y2rwxyQazfxPDpRnSd1PrRrczhgLPrgVy-rbG0swyFAfjaCOkdTFCaaVZUzcK0af_oFdpnSOWh1TNeV1LNvtLDXYEgy1P-K7bipq5njGteTPTSB3_h8K1nYVLEXzA872E53sJyEzwYxrsuhTz7uPpPit2rMuplAz-ph-cma3RzM5oBgdlfhvN1Jj05HYnb1L-OEv-Ao80y78</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471177305</pqid></control><display><type>article</type><title>Early cases of SARS-CoV-2 infection in Uganda: epidemiology and lessons learned from risk-based testing approaches - March-April 2020</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Migisha, Richard ; Kwesiga, Benon ; Mirembe, Bernadette Basuta ; Amanya, Geofrey ; Kabwama, Steven N ; Kadobera, Daniel ; Bulage, Lilian ; Nsereko, Godfrey ; Wadunde, Ignatius ; Tindyebwa, Tonny ; Lubwama, Bernard ; Kagirita, Atek A ; Kayiwa, John T ; Lutwama, Julius J ; Boore, Amy L ; Harris, Julie R ; Bosa, Henry Kyobe ; Ario, Alex Riolexus</creator><creatorcontrib>Migisha, Richard ; Kwesiga, Benon ; Mirembe, Bernadette Basuta ; Amanya, Geofrey ; Kabwama, Steven N ; Kadobera, Daniel ; Bulage, Lilian ; Nsereko, Godfrey ; Wadunde, Ignatius ; Tindyebwa, Tonny ; Lubwama, Bernard ; Kagirita, Atek A ; Kayiwa, John T ; Lutwama, Julius J ; Boore, Amy L ; Harris, Julie R ; Bosa, Henry Kyobe ; Ario, Alex Riolexus</creatorcontrib><description>On March 13, 2020, Uganda instituted COVID-19 symptom screening at its international airport, isolation and SARS-CoV-2 testing for symptomatic persons, and mandatory 14-day quarantine and testing of persons traveling through or from high-risk countries. On March 21, 2020, Uganda reported its first SARS-CoV-2 infection in a symptomatic traveler from Dubai. By April 12, 2020, 54 cases and 1257 contacts were identified. We describe the epidemiological, clinical, and transmission characteristics of these cases.
A confirmed case was laboratory-confirmed SARS-CoV-2 infection during March 21-April 12, 2020 in a resident of or traveler to Uganda. We reviewed case-person files and interviewed case-persons at isolation centers. We identified infected contacts from contact tracing records.
Mean case-person age was 35 (±16) years; 34 (63%) were male. Forty-five (83%) had recently traveled internationally ('imported cases'), five (9.3%) were known contacts of travelers, and four (7.4%) were community cases. Of the 45 imported cases, only one (2.2%) was symptomatic at entry. Among all case-persons, 29 (54%) were symptomatic at testing and five (9.3%) were pre-symptomatic. Among the 34 (63%) case-persons who were ever symptomatic, all had mild disease: 16 (47%) had fever, 13 (38%) reported headache, and 10 (29%) reported cough. Fifteen (28%) case-persons had underlying conditions, including three persons with HIV. An average of 31 contacts (range, 4-130) were identified per case-person. Five (10%) case-persons, all symptomatic, infected one contact each.
The first 54 case-persons with SARS-CoV-2 infection in Uganda primarily comprised incoming air travelers with asymptomatic or mild disease. Disease would likely not have been detected in these persons without the targeted testing interventions implemented in Uganda. Transmission was low among symptomatic persons and nonexistent from asymptomatic persons. Routine, systematic screening of travelers and at-risk persons, and thorough contact tracing will be needed for Uganda to maintain epidemic control.</description><identifier>ISSN: 1744-8603</identifier><identifier>EISSN: 1744-8603</identifier><identifier>DOI: 10.1186/s12992-020-00643-7</identifier><identifier>PMID: 33239041</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Airports ; Asymptomatic ; Child ; Comorbidity ; Contact Tracing ; Coronavirus Infections ; Coronaviruses ; Cough ; COVID-19 ; COVID-19 - complications ; COVID-19 - diagnosis ; COVID-19 - epidemiology ; COVID-19 - virology ; COVID-19 Testing ; Diabetes ; Disease control ; Disease transmission ; Epidemics ; Epidemiology ; Female ; Fever ; HIV ; Hospitals ; Human immunodeficiency virus ; Humans ; Hypertension ; Illnesses ; Infections ; Laboratories ; Male ; Mass Screening - methods ; Middle Aged ; Pandemics ; Passenger screening ; Public health ; Quarantine ; Respiratory diseases ; Risk ; Risk Factors ; SARS-CoV-2 ; Screening ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Travel ; Uganda - epidemiology ; Viral diseases ; Young Adult</subject><ispartof>Globalization and health, 2020-11, Vol.16 (1), p.114, Article 114</ispartof><rights>COPYRIGHT 2020 BioMed Central Ltd.</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c531t-b22fdb418681244bc69d04b3d0f4ed4e0efb0e4318c7eaf98283b3af40937d133</citedby><cites>FETCH-LOGICAL-c531t-b22fdb418681244bc69d04b3d0f4ed4e0efb0e4318c7eaf98283b3af40937d133</cites><orcidid>0000-0003-1709-9521</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686950/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686950/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33239041$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Migisha, Richard</creatorcontrib><creatorcontrib>Kwesiga, Benon</creatorcontrib><creatorcontrib>Mirembe, Bernadette Basuta</creatorcontrib><creatorcontrib>Amanya, Geofrey</creatorcontrib><creatorcontrib>Kabwama, Steven N</creatorcontrib><creatorcontrib>Kadobera, Daniel</creatorcontrib><creatorcontrib>Bulage, Lilian</creatorcontrib><creatorcontrib>Nsereko, Godfrey</creatorcontrib><creatorcontrib>Wadunde, Ignatius</creatorcontrib><creatorcontrib>Tindyebwa, Tonny</creatorcontrib><creatorcontrib>Lubwama, Bernard</creatorcontrib><creatorcontrib>Kagirita, Atek A</creatorcontrib><creatorcontrib>Kayiwa, John T</creatorcontrib><creatorcontrib>Lutwama, Julius J</creatorcontrib><creatorcontrib>Boore, Amy L</creatorcontrib><creatorcontrib>Harris, Julie R</creatorcontrib><creatorcontrib>Bosa, Henry Kyobe</creatorcontrib><creatorcontrib>Ario, Alex Riolexus</creatorcontrib><title>Early cases of SARS-CoV-2 infection in Uganda: epidemiology and lessons learned from risk-based testing approaches - March-April 2020</title><title>Globalization and health</title><addtitle>Global Health</addtitle><description>On March 13, 2020, Uganda instituted COVID-19 symptom screening at its international airport, isolation and SARS-CoV-2 testing for symptomatic persons, and mandatory 14-day quarantine and testing of persons traveling through or from high-risk countries. On March 21, 2020, Uganda reported its first SARS-CoV-2 infection in a symptomatic traveler from Dubai. By April 12, 2020, 54 cases and 1257 contacts were identified. We describe the epidemiological, clinical, and transmission characteristics of these cases.
A confirmed case was laboratory-confirmed SARS-CoV-2 infection during March 21-April 12, 2020 in a resident of or traveler to Uganda. We reviewed case-person files and interviewed case-persons at isolation centers. We identified infected contacts from contact tracing records.
Mean case-person age was 35 (±16) years; 34 (63%) were male. Forty-five (83%) had recently traveled internationally ('imported cases'), five (9.3%) were known contacts of travelers, and four (7.4%) were community cases. Of the 45 imported cases, only one (2.2%) was symptomatic at entry. Among all case-persons, 29 (54%) were symptomatic at testing and five (9.3%) were pre-symptomatic. Among the 34 (63%) case-persons who were ever symptomatic, all had mild disease: 16 (47%) had fever, 13 (38%) reported headache, and 10 (29%) reported cough. Fifteen (28%) case-persons had underlying conditions, including three persons with HIV. An average of 31 contacts (range, 4-130) were identified per case-person. Five (10%) case-persons, all symptomatic, infected one contact each.
The first 54 case-persons with SARS-CoV-2 infection in Uganda primarily comprised incoming air travelers with asymptomatic or mild disease. Disease would likely not have been detected in these persons without the targeted testing interventions implemented in Uganda. Transmission was low among symptomatic persons and nonexistent from asymptomatic persons. Routine, systematic screening of travelers and at-risk persons, and thorough contact tracing will be needed for Uganda to maintain epidemic control.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Airports</subject><subject>Asymptomatic</subject><subject>Child</subject><subject>Comorbidity</subject><subject>Contact Tracing</subject><subject>Coronavirus Infections</subject><subject>Coronaviruses</subject><subject>Cough</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - virology</subject><subject>COVID-19 Testing</subject><subject>Diabetes</subject><subject>Disease control</subject><subject>Disease transmission</subject><subject>Epidemics</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Fever</subject><subject>HIV</subject><subject>Hospitals</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Illnesses</subject><subject>Infections</subject><subject>Laboratories</subject><subject>Male</subject><subject>Mass Screening - methods</subject><subject>Middle Aged</subject><subject>Pandemics</subject><subject>Passenger screening</subject><subject>Public health</subject><subject>Quarantine</subject><subject>Respiratory diseases</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>SARS-CoV-2</subject><subject>Screening</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Travel</subject><subject>Uganda - epidemiology</subject><subject>Viral diseases</subject><subject>Young Adult</subject><issn>1744-8603</issn><issn>1744-8603</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>KPI</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptks9uEzEQxlcIREvhBTggS1zg4OJ_8e5yQIqiAhVFIEq5Wl7veOuysYO9QeQBeG8mpJQGIR88sn_z2TPzVdVjzo45b_SLwkXbCsoEo4xpJWl9pzrktVK00UzevRUfVA9KuWJMMSXb-9WBlEK2TPHD6ueJzeOGOFugkOTJ-fzTOV2kL1SQED24KaSIEbkYbOztSwKr0MMypDENG4JHZIRSUiy42xyhJz6nJcmhfKUdavZkgjKFOBC7WuVk3SU-Q8l7m90lna9yGInA_z-s7nk7Fnh0vR9VF69PPi_e0rMPb04X8zPqZpJPtBPC953C2hsulOqcbnumOtkzr6BXwMB3DJTkjavB-rYRjeyk9Yq1su65lEfVq53uat0toXcQp2xHg_9Y2rwxyQazfxPDpRnSd1PrRrczhgLPrgVy-rbG0swyFAfjaCOkdTFCaaVZUzcK0af_oFdpnSOWh1TNeV1LNvtLDXYEgy1P-K7bipq5njGteTPTSB3_h8K1nYVLEXzA872E53sJyEzwYxrsuhTz7uPpPit2rMuplAz-ph-cma3RzM5oBgdlfhvN1Jj05HYnb1L-OEv-Ao80y78</recordid><startdate>20201125</startdate><enddate>20201125</enddate><creator>Migisha, Richard</creator><creator>Kwesiga, Benon</creator><creator>Mirembe, Bernadette Basuta</creator><creator>Amanya, Geofrey</creator><creator>Kabwama, Steven N</creator><creator>Kadobera, Daniel</creator><creator>Bulage, Lilian</creator><creator>Nsereko, Godfrey</creator><creator>Wadunde, Ignatius</creator><creator>Tindyebwa, Tonny</creator><creator>Lubwama, Bernard</creator><creator>Kagirita, Atek A</creator><creator>Kayiwa, John T</creator><creator>Lutwama, Julius J</creator><creator>Boore, Amy L</creator><creator>Harris, Julie R</creator><creator>Bosa, Henry Kyobe</creator><creator>Ario, Alex Riolexus</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>KPI</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PATMY</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PYCSY</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1709-9521</orcidid></search><sort><creationdate>20201125</creationdate><title>Early cases of SARS-CoV-2 infection in Uganda: epidemiology and lessons learned from risk-based testing approaches - March-April 2020</title><author>Migisha, Richard ; Kwesiga, Benon ; Mirembe, Bernadette Basuta ; Amanya, Geofrey ; Kabwama, Steven N ; Kadobera, Daniel ; Bulage, Lilian ; Nsereko, Godfrey ; Wadunde, Ignatius ; Tindyebwa, Tonny ; Lubwama, Bernard ; Kagirita, Atek A ; Kayiwa, John T ; Lutwama, Julius J ; Boore, Amy L ; Harris, Julie R ; Bosa, Henry Kyobe ; Ario, Alex Riolexus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c531t-b22fdb418681244bc69d04b3d0f4ed4e0efb0e4318c7eaf98283b3af40937d133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Airports</topic><topic>Asymptomatic</topic><topic>Child</topic><topic>Comorbidity</topic><topic>Contact Tracing</topic><topic>Coronavirus Infections</topic><topic>Coronaviruses</topic><topic>Cough</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - virology</topic><topic>COVID-19 Testing</topic><topic>Diabetes</topic><topic>Disease control</topic><topic>Disease transmission</topic><topic>Epidemics</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Fever</topic><topic>HIV</topic><topic>Hospitals</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Illnesses</topic><topic>Infections</topic><topic>Laboratories</topic><topic>Male</topic><topic>Mass Screening - methods</topic><topic>Middle Aged</topic><topic>Pandemics</topic><topic>Passenger screening</topic><topic>Public health</topic><topic>Quarantine</topic><topic>Respiratory diseases</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>SARS-CoV-2</topic><topic>Screening</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Travel</topic><topic>Uganda - epidemiology</topic><topic>Viral diseases</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Migisha, Richard</creatorcontrib><creatorcontrib>Kwesiga, Benon</creatorcontrib><creatorcontrib>Mirembe, Bernadette Basuta</creatorcontrib><creatorcontrib>Amanya, Geofrey</creatorcontrib><creatorcontrib>Kabwama, Steven N</creatorcontrib><creatorcontrib>Kadobera, Daniel</creatorcontrib><creatorcontrib>Bulage, Lilian</creatorcontrib><creatorcontrib>Nsereko, Godfrey</creatorcontrib><creatorcontrib>Wadunde, Ignatius</creatorcontrib><creatorcontrib>Tindyebwa, Tonny</creatorcontrib><creatorcontrib>Lubwama, Bernard</creatorcontrib><creatorcontrib>Kagirita, Atek A</creatorcontrib><creatorcontrib>Kayiwa, John T</creatorcontrib><creatorcontrib>Lutwama, Julius J</creatorcontrib><creatorcontrib>Boore, Amy L</creatorcontrib><creatorcontrib>Harris, Julie R</creatorcontrib><creatorcontrib>Bosa, Henry Kyobe</creatorcontrib><creatorcontrib>Ario, Alex Riolexus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Global Issues</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Environmental Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Environmental Science Collection</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Globalization and health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Migisha, Richard</au><au>Kwesiga, Benon</au><au>Mirembe, Bernadette Basuta</au><au>Amanya, Geofrey</au><au>Kabwama, Steven N</au><au>Kadobera, Daniel</au><au>Bulage, Lilian</au><au>Nsereko, Godfrey</au><au>Wadunde, Ignatius</au><au>Tindyebwa, Tonny</au><au>Lubwama, Bernard</au><au>Kagirita, Atek A</au><au>Kayiwa, John T</au><au>Lutwama, Julius J</au><au>Boore, Amy L</au><au>Harris, Julie R</au><au>Bosa, Henry Kyobe</au><au>Ario, Alex Riolexus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early cases of SARS-CoV-2 infection in Uganda: epidemiology and lessons learned from risk-based testing approaches - March-April 2020</atitle><jtitle>Globalization and health</jtitle><addtitle>Global Health</addtitle><date>2020-11-25</date><risdate>2020</risdate><volume>16</volume><issue>1</issue><spage>114</spage><pages>114-</pages><artnum>114</artnum><issn>1744-8603</issn><eissn>1744-8603</eissn><abstract>On March 13, 2020, Uganda instituted COVID-19 symptom screening at its international airport, isolation and SARS-CoV-2 testing for symptomatic persons, and mandatory 14-day quarantine and testing of persons traveling through or from high-risk countries. On March 21, 2020, Uganda reported its first SARS-CoV-2 infection in a symptomatic traveler from Dubai. By April 12, 2020, 54 cases and 1257 contacts were identified. We describe the epidemiological, clinical, and transmission characteristics of these cases.
A confirmed case was laboratory-confirmed SARS-CoV-2 infection during March 21-April 12, 2020 in a resident of or traveler to Uganda. We reviewed case-person files and interviewed case-persons at isolation centers. We identified infected contacts from contact tracing records.
Mean case-person age was 35 (±16) years; 34 (63%) were male. Forty-five (83%) had recently traveled internationally ('imported cases'), five (9.3%) were known contacts of travelers, and four (7.4%) were community cases. Of the 45 imported cases, only one (2.2%) was symptomatic at entry. Among all case-persons, 29 (54%) were symptomatic at testing and five (9.3%) were pre-symptomatic. Among the 34 (63%) case-persons who were ever symptomatic, all had mild disease: 16 (47%) had fever, 13 (38%) reported headache, and 10 (29%) reported cough. Fifteen (28%) case-persons had underlying conditions, including three persons with HIV. An average of 31 contacts (range, 4-130) were identified per case-person. Five (10%) case-persons, all symptomatic, infected one contact each.
The first 54 case-persons with SARS-CoV-2 infection in Uganda primarily comprised incoming air travelers with asymptomatic or mild disease. Disease would likely not have been detected in these persons without the targeted testing interventions implemented in Uganda. Transmission was low among symptomatic persons and nonexistent from asymptomatic persons. Routine, systematic screening of travelers and at-risk persons, and thorough contact tracing will be needed for Uganda to maintain epidemic control.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>33239041</pmid><doi>10.1186/s12992-020-00643-7</doi><orcidid>https://orcid.org/0000-0003-1709-9521</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1744-8603 |
| ispartof | Globalization and health, 2020-11, Vol.16 (1), p.114, Article 114 |
| issn | 1744-8603 1744-8603 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7686950 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; SpringerNature Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adolescent Adult Aged Airports Asymptomatic Child Comorbidity Contact Tracing Coronavirus Infections Coronaviruses Cough COVID-19 COVID-19 - complications COVID-19 - diagnosis COVID-19 - epidemiology COVID-19 - virology COVID-19 Testing Diabetes Disease control Disease transmission Epidemics Epidemiology Female Fever HIV Hospitals Human immunodeficiency virus Humans Hypertension Illnesses Infections Laboratories Male Mass Screening - methods Middle Aged Pandemics Passenger screening Public health Quarantine Respiratory diseases Risk Risk Factors SARS-CoV-2 Screening Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Travel Uganda - epidemiology Viral diseases Young Adult |
| title | Early cases of SARS-CoV-2 infection in Uganda: epidemiology and lessons learned from risk-based testing approaches - March-April 2020 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T00%3A37%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20cases%20of%20SARS-CoV-2%20infection%20in%20Uganda:%20epidemiology%20and%20lessons%20learned%20from%20risk-based%20testing%20approaches%20-%20March-April%202020&rft.jtitle=Globalization%20and%20health&rft.au=Migisha,%20Richard&rft.date=2020-11-25&rft.volume=16&rft.issue=1&rft.spage=114&rft.pages=114-&rft.artnum=114&rft.issn=1744-8603&rft.eissn=1744-8603&rft_id=info:doi/10.1186/s12992-020-00643-7&rft_dat=%3Cgale_pubme%3EA650661856%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471177305&rft_id=info:pmid/33239041&rft_galeid=A650661856&rfr_iscdi=true |